Barclays Miami: Electra Therapeutics has taken a novel approach to target Signal Regulatory Proteins (SIRPs). It's in a pivotal for its first indication right now
President and CEO Kathy Dong describes the function of SIRPs and how Electra is targeting them with antibodies. Plus, an overview of the company's privotal program against secondary Hemophagocytic Lymphohistiocytosis (sHLH).
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.